CAMBRIDGE, Mass.–(BUSINESS WIRE)–Universal DX (“UDX”), a biotech company dedicated to transforming cancer into a curable disease by detecting it early, today announced closure of the Series B which funds the clinical trial for its colorectal cancer screening blood test, Signal-C®, aimed at achieving FDA premarket approval. The clinical trial for Signal-C® (https://clinicaltrials.gov/study/NCT06059963) is well under way and recruited its first patient in January 2024. The study is on target to reach its recruiting goal of enrolling at least 15,000 patients across 100 investigator sites.
Universal DX Initiates Clinical Trial for FDA Approval of Signal-C® Colorectal Cancer Screening Blood Test
